EpiPlex Platform Development

About Alida Biosciences

Alida Biosciences is an early-stage biotech company pioneering tools for epitranscriptomics, the study of RNA modifications. Its core technology, the EpiPlex™ platform, employs proximity barcoding and engineered protein binders to convert sequencing-silent RNA modifications into readable barcodes, enabling multi-target detection from standard short-read RNA-seq data. The company is positioning its platform to serve basic research, biomarker discovery, and drug development, particularly in oncology, neurology, and immunology, as evidenced by a recent strategic collaboration with STORM Therapeutics. AlidaBio operates as a private, pre-revenue platform company targeting the growing market for RNA analysis tools.

Therapeutic Areas